CNBC Investing Club: Cramer’s Morning Take on Home Depot 3/31/26

SPEAKER_1 (0:00)

Trading at Schwab is powered by Ameritrade, giving you even more specialized support than ever before. Like access to the trade desk. Our team of passionate traders ready to tackle anything from the most complex trading questions to a simple strategy gut check. Need assistance? No problem. Get 24-7 professional answers and live help, and access support by phone, email, and in-platform chat. That's how Schwab is here for you, to help you trade brilliantly. Learn more at schwab.com/trading.

SPEAKER_2 (0:28)

Thy ticket, Lady Jennifer of Coolidge.

Jim Cramer (0:31)

Well, many thanks, good sir.

SPEAKER_4 (0:33)

Heareth my Discover card.

SPEAKER_1 (0:36)

They accept Discover at Renaissance Fairs?

SPEAKER_2 (0:38)

Yeah, they do here.

Jim Cramer (0:40)

Discover is accepted at the places I love to shop.

SPEAKER_2 (0:42)

Get it with the times.

SPEAKER_1 (0:45)

With the times?

SPEAKER_5 (0:46)

You're playing the lute.

SPEAKER_2 (0:49)

Yeah, and it sounds pretty good, right?

SPEAKER_5 (0:51)

Discover is accepted at 99 percent of places that take credit cards nationwide. Based on the February 2025 Nielsen Report.

Jim Cramer (1:00)

Jim Cramer here to share a short preview of my take on the market from today's Members Only CNBC Investing Club morning meeting. Join the club for full access to the morning meeting every day at 10:20 a.m. Visit cnbc.com/morningtake to sign up today. That's one word, morning take. It's pretty much a fulcrum day.

Fulcrum because if the president decides that the Strait of Hormuz doesn't have to be open, which is what we hear, well that presents a lot of different opportunities. It makes it so that the market has quite a different coloration, including oil coming down. Oil coming down is going to relieve the inflation problem. To relieve the inflation problem, you don't want to buy Home Depot. You're going to want to buy Toll Brothers. You're going to want to buy anything home-oriented, anything retail-oriented. And that's the market we have right now, with the exception of the fact that the hyperscalers are all doing well.

SPEAKER_2 (1:52)

Yeah, we'll see. And this news, of course, comes after the Wall Street Journal reported that Trump has told Aides that he's willing to end the war without reopening the Strait.

Jim Cramer (2:00)

You know, that's extraordinary.

It's been, along with nukes, it's breakable. It's a no-deal without it. And suddenly, you start thinking to yourself, that's how he's going to get out of it. He's not going to negotiate the Strait, he's just going to go.

SPEAKER_2 (2:15)

We're looking for ways to off-ramp a war that has been this entire month. And, of course, March has been a very bad month for stocks. Oscillator moved back to oversold territory yesterday. So, you know, maybe this is part oversold bounce here. We also have...

Jim Cramer (2:33)

Well, I mean, that's dangerous, obviously, right? Because without follow-through, and the president starts bombing things again, these will all be repealed.

SPEAKER_2 (2:42)

Yes. And that's the tricky part to this market, is how much it is influenced by this military campaign, and the impact it has on oil. Oil, by the way, today, relatively unchanged, crossed above 100 yesterday, WTI.

Jim Cramer (2:58)

In the air, remember, I tell you to look at some oil companies, they go a little bit ahead of the future. Chevron, I don't know if you have a picture of Chevron, but that's been the one that leads everything up, and you can say, oh, my, I guess things are going to start coming down with Chevron. But there's crazy things happening.

SPEAKER_4 (3:16)

All opinions expressed by Jim Cramer on this podcast and in connection with the CNBC Investing Club are solely Cramer's opinions and do not reflect the opinions of CNBC or its parent company or affiliates, and may have been previously disseminated by Cramer on television, radio, internet or another medium. No specific outcome or profit is guaranteed in connection with your reliance upon or other use of the content from Cramer. The opinions offered in connection with this podcast and the CNBC Investing Club are not an attempt to induce any particular trading behavior, investment or strategy. To view the full CNBC Investing Club disclaimer, please visit cnbc.com/investingclubdisclaimer.

SPEAKER_5 (3:48)

Snoring, gasping during sleep, feeling fatigued? Wake up to ZepBound Terzepatide, the first and only FDA approved prescription medicine for moderate to severe obstructive sleep apnea, OSA and adults with obesity. ZepBound is an injectable prescription medicine that may help adults with moderate to severe obstructive sleep apnea, OSA and obesity to improve their OSA. ZepBound should be used with a reduced calorie diet and increased physical activity. ZepBound is approved as a 2.5, 5, 7.5, 10, 12.5 or 15 milligram injection. ZepBound contains terzepotide and should not be used with other terzepotide containing products or any GLP-1 receptor agonist medicines. It is not known if ZepBound is safe and effective for use in children. Do not share needles or pens or reuse needles. Don't take ZepBound if allergic to it or if you or someone in your family had medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2 Tell your doctor if you get a lump or swelling in your neck. Stop ZepBound and call your doctor if you have severe stomach pain or a serious allergic reaction. Severe side effects may include inflamed pancreas or gallbladder problems. Tell your doctor if you experience vision changes, depression or suicidal thoughts before scheduled procedures with anesthesia. If you're nursing, pregnant, plan to be or taking birth control pills. Taking ZepBound with a sulfonylurea or insulin may cause low blood sugar. Side effects include nausea, diarrhea and vomiting, which can cause dehydration and worsen kidney problems. Talk to your doctor. Call 1-800-545-5979 or visit zepbound.lily.com. ZepBound and its delivery device base and quick pin are registered trademarks owned or licensed by Eli Lilly & Company. It's subsidiaries or affiliates.